SAN
DIEGO, March 24, 2022 /PRNewswire/ -- Inhibrx,
Inc. (Nasdaq: INBX), a biotechnology company with four clinical
programs in development and an emerging pre-clinical pipeline,
announced today that data from INBRX-121 and INBRX-130 will be
presented at the 2022 American Association for Cancer Research
("AACR") Annual Meeting to be held April
8th- 13th, 2022 in New Orleans, LA.
"We are excited to share some of the updated preclinical data
for our targeted cytokine platform and INBRX-121 that specifically
expands and enhances the cytotoxic capacity of NK cells.
Additionally, we will introduce our unique T-cell engager
platform, CONTRA-MAB®, and INBRX-130 that
targets the 5T4 antigen on solid tumors," said Brendan
Eckelman, Ph.D., Inhibrx Co-founder and Chief Scientific Officer.
"We believe that both of these platforms are foundational to our
continued efforts aimed at growing our emerging pipeline of
therapeutic candidates in oncology."
Details on poster presentations are shared below:
Title: INBRX-121, a safe and efficacious molecular
targeted cytokine that enhances NK cell-mediated tumor
killing
Track/Session: Immunology - Immunomodulatory
Agents and Interventions 2
Abstract/Poster: 3513 /
15
Lead Author: Heather
Kinkead
Date & Time: April 12, 2022, 1:30-5:00
PM CDT
Location: Exhibit Halls, Poster Section
37
Title: INBRX-130, a 5T4-targeted CONTRA-MAB, is a
potent CD3 bispecific antibody engineered to have minimal off-tumor
activity
Track/Session: Immunology - Therapeutic
Antibodies 2
Abstract/Poster: 2912 / 27
Lead
Author: Katelyn M.
Willis
Date & Time: April 12, 2022, 9:00 AM-
12:30 PM CDT
Location: Exhibit Halls, Poster
Section 38
Posters will be available on-demand on the AACR website for
attendees (www.aacr.org) beginning at 12:00
PM CDT on April 8, 2022 until
July 13, 2022. Upon release at AACR,
the scientific posters will be accessible through Inhibrx's website
at https://inhibrx.investorroom.com/events-and-presentations.
About INBRX-121
Inhibrx developed a molecular
targeted cytokine ("MTC") platform that combines an engineered IL-2
variant with reduced affinity for the IL-2 receptor and high
affinity sdAbs to restrict IL-2 receptor signaling to cells
expressing the target antigen (termed cis-signaling). Inhibrx's MTC
platform provides a novel path to overcoming the limitations of
IL-2 therapy through the pinpointed delivery of IL-2 activity to
target cells of interest. INBRX-121 is an MTC designed to
deliver IL-2 to NK cells using an NKp46-specific sdAb as the
targeting moiety. INBRX-121 drives specific NK cell expansion and
enhances activation and cytotoxic capacity. Unlike T cells,
tumor recognition by NK cells is independent of MHC-presented
antigens and can elicit immediate cytotoxic activity. Further, many
of the toxicities associated with T cell therapeutics have not been
observed with NK-centric treatments. Due to its unique design,
INBRX-121 has the potential to be a safe and efficacious treatment
option for a broad array of cancer indications both as a
monotherapy and in combination with ADCC-enabled antibodies.
About INBRX-130
Inhibrx has developed a CD3 bispecific
platform, CONTRA-MAB®
(Constrained T Cell Redirecting
and Activating Multispecific Antibody), that
combines tumor-associated antigen targeting single-domain
antibodies (sdAbs) with a constrained CD3-targeting VH/VL pair
that has been strategically positioned and affinity engineered to
minimize T cell activation and cytokine production in the absence
of target antigen engagement. INBRX-130 is a CONTRA-MAB® that
targets trophoblast glycoprotein (TPBG; 5T4), a cell-surface
protein that is upregulated across many solid tumor indications but
has restricted expression on normal adult tissues. Due to the
unique CONTRA-MAB® design and the broad tumor biased expression of
5T4 across solid tumors, INBRX-130, has the potential to have a
greater therapeutic index over other T-cell directed therapeutics
in the solid tumor setting and thereby provide a significant
benefit to patients in need.
About Inhibrx, Inc.
Inhibrx is a clinical-stage
biotechnology company focused on developing a broad pipeline of
novel biologic therapeutic candidates in oncology and orphan
diseases. Inhibrx utilizes diverse methods of protein engineering
to address the specific requirements of complex target and disease
biology, including its proprietary sdAb platform. Inhibrx has
collaborations with 2seventy bio (formerly bluebird bio),
Bristol-Myers Squibb and Chiesi. For more information, please visit
www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-details-of-presentations-at-2022-aacr-annual-meeting-301510333.html
SOURCE Inhibrx Inc.